Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Population pharmacokinetics of a combination of miltefosine and paromomycin in Eastern African children and adults with visceral leishmaniasis.
Verrest L, Roseboom IC, Wasunna M, Mbui J, Njenga S, Musa AM, Olobo J, Mohammed R, Ritmeijer K, Chu WY, Huitema ADR, Solomos A, Alves F, Dorlo TPC. Verrest L, et al. Among authors: solomos a. J Antimicrob Chemother. 2023 Nov 6;78(11):2702-2714. doi: 10.1093/jac/dkad286. J Antimicrob Chemother. 2023. PMID: 37726401 Free PMC article. Clinical Trial.
Pharmacokinetics, Safety, and Efficacy of an Allometric Miltefosine Regimen for the Treatment of Visceral Leishmaniasis in Eastern African Children: An Open-label, Phase II Clinical Trial.
Mbui J, Olobo J, Omollo R, Solomos A, Kip AE, Kirigi G, Sagaki P, Kimutai R, Were L, Omollo T, Egondi TW, Wasunna M, Alvar J, Dorlo TPC, Alves F. Mbui J, et al. Among authors: solomos a. Clin Infect Dis. 2019 Apr 24;68(9):1530-1538. doi: 10.1093/cid/ciy747. Clin Infect Dis. 2019. PMID: 30188978 Free PMC article. Clinical Trial.
Paromomycin and Miltefosine Combination as an Alternative to Treat Patients With Visceral Leishmaniasis in Eastern Africa: A Randomized, Controlled, Multicountry Trial.
Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Alcoba G, Muthoni Ouattara G, Egondi T, Nakanwagi P, Omollo T, Wasunna M, Verrest L, Dorlo TPC, Musa Younis B, Nour A, Taha Ahmed Elmukashfi E, Ismail Omer Haroun A, Khalil EAG, Njenga S, Fikre H, Mekonnen T, Mersha D, Sisay K, Sagaki P, Alvar J, Solomos A, Alves F. Musa AM, et al. Among authors: solomos a. Clin Infect Dis. 2023 Feb 8;76(3):e1177-e1185. doi: 10.1093/cid/ciac643. Clin Infect Dis. 2023. PMID: 36164254 Free PMC article. Clinical Trial.
Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.
Alves F, Bilbe G, Blesson S, Goyal V, Monnerat S, Mowbray C, Muthoni Ouattara G, Pécoul B, Rijal S, Rode J, Solomos A, Strub-Wourgaft N, Wasunna M, Wells S, Zijlstra EE, Arana B, Alvar J. Alves F, et al. Among authors: solomos a. Clin Microbiol Rev. 2018 Aug 29;31(4):e00048-18. doi: 10.1128/CMR.00048-18. Print 2018 Oct. Clin Microbiol Rev. 2018. PMID: 30158301 Free PMC article. Review.
Disease-specific differences in pharmacokinetics of paromomycin and miltefosine between post-kala-azar dermal leishmaniasis and visceral leishmaniasis patients in eastern Africa.
Chu WY, Verrest L, Younis BM, Musa AM, Mbui J, Mohammed R, Olobo J, Ritmeijer K, Monnerat S, Wasunna M, Roseboom IC, Solomos A, Huitema ADR, Alves F, Dorlo TPC. Chu WY, et al. Among authors: solomos a. J Infect Dis. 2024 Aug 21:jiae413. doi: 10.1093/infdis/jiae413. Online ahead of print. J Infect Dis. 2024. PMID: 39166299